Karyopharm Therapeutics (KPTI) Total Liabilities (2012 - 2025)

Karyopharm Therapeutics has reported Total Liabilities for 14 years, with the latest figure at $401.3 million in Q4 2025.

• For the quarter ending Q4 2025, Total Liabilities rose 14.53% year-over-year to $401.3 million; the trailing twelve-month figure through Dec 2025 stood at $401.3 million (up 14.53% YoY), and the FY2025 full-year result was $401.3 million, up 14.53% from the prior year.
• Total Liabilities for Q4 2025 stood at $401.3 million, up from $365.5 million in the prior quarter.
• The five-year high for Total Liabilities was $401.3 million in Q4 2025, with the low at $314.5 million in Q1 2021.
• Historically, Total Liabilities has averaged $364.8 million across 5 years, with a median of $370.7 million in 2023.
• Annual changes were most pronounced in 2021 — Total Liabilities soared 49.74% — and 2025, when it fell 10.66%.
• Karyopharm Therapeutics' Total Liabilities stood at $385.0 million in 2021, then slipped by 2.64% to $374.8 million in 2022, then climbed by 0.48% to $376.6 million in 2023, then declined by 6.96% to $350.4 million in 2024, then increased by 14.53% to $401.3 million in 2025.
• The last three Total Liabilities figures came in at $401.3 million (Q4 2025), $365.5 million (Q3 2025), and $343.8 million (Q2 2025), per Business Quant data.